vs

Side-by-side financial comparison of Playtika Holding Corp. (PLTK) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Playtika Holding Corp. is the larger business by last-quarter revenue ($678.8M vs $622.0M, roughly 1.1× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -45.6%, a 80.0% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 4.4%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 2.1%).

Playtika Holding Corp. is an Israeli digital entertainment company specializing in the development and publication of mobile games. In 2021, Playtika had over 35 million monthly active users.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

PLTK vs RPRX — Head-to-Head

Bigger by revenue
PLTK
PLTK
1.1× larger
PLTK
$678.8M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+0.4% gap
RPRX
4.8%
4.4%
PLTK
Higher net margin
RPRX
RPRX
80.0% more per $
RPRX
34.4%
-45.6%
PLTK
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
2.1%
PLTK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PLTK
PLTK
RPRX
RPRX
Revenue
$678.8M
$622.0M
Net Profit
$-309.3M
$214.2M
Gross Margin
72.5%
Operating Margin
-41.4%
62.4%
Net Margin
-45.6%
34.4%
Revenue YoY
4.4%
4.8%
Net Profit YoY
-1752.1%
2.9%
EPS (diluted)
$-0.83
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PLTK
PLTK
RPRX
RPRX
Q4 25
$678.8M
$622.0M
Q3 25
$674.6M
$609.3M
Q2 25
$696.0M
$578.7M
Q1 25
$706.0M
$568.2M
Q4 24
$650.3M
$593.6M
Q3 24
$620.8M
$564.7M
Q2 24
$627.0M
$537.3M
Q1 24
$651.2M
$568.0M
Net Profit
PLTK
PLTK
RPRX
RPRX
Q4 25
$-309.3M
$214.2M
Q3 25
$39.1M
$288.2M
Q2 25
$33.2M
$30.2M
Q1 25
$30.6M
$238.3M
Q4 24
$-16.7M
$208.2M
Q3 24
$39.3M
$544.0M
Q2 24
$86.6M
$102.0M
Q1 24
$53.0M
$4.8M
Gross Margin
PLTK
PLTK
RPRX
RPRX
Q4 25
72.5%
Q3 25
73.6%
Q2 25
71.9%
Q1 25
72.0%
Q4 24
72.5%
Q3 24
72.9%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
PLTK
PLTK
RPRX
RPRX
Q4 25
-41.4%
62.4%
Q3 25
14.6%
70.1%
Q2 25
15.8%
36.3%
Q1 25
9.6%
94.0%
Q4 24
8.5%
60.9%
Q3 24
15.7%
Q2 24
22.4%
50.2%
Q1 24
15.1%
-13.0%
Net Margin
PLTK
PLTK
RPRX
RPRX
Q4 25
-45.6%
34.4%
Q3 25
5.8%
47.3%
Q2 25
4.8%
5.2%
Q1 25
4.3%
41.9%
Q4 24
-2.6%
35.1%
Q3 24
6.3%
96.3%
Q2 24
13.8%
19.0%
Q1 24
8.1%
0.8%
EPS (diluted)
PLTK
PLTK
RPRX
RPRX
Q4 25
$-0.83
$0.49
Q3 25
$0.11
$0.67
Q2 25
$0.09
$0.07
Q1 25
$0.08
$0.55
Q4 24
$-0.04
$0.46
Q3 24
$0.11
$1.21
Q2 24
$0.23
$0.23
Q1 24
$0.14
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PLTK
PLTK
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$684.2M
$618.7M
Total DebtLower is stronger
$2.4B
$9.0B
Stockholders' EquityBook value
$-411.4M
$9.7B
Total Assets
$3.7B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PLTK
PLTK
RPRX
RPRX
Q4 25
$684.2M
$618.7M
Q3 25
$587.9M
$938.9M
Q2 25
$500.9M
$631.9M
Q1 25
$434.8M
$1.1B
Q4 24
$565.8M
$929.0M
Q3 24
$1.1B
$950.1M
Q2 24
$710.3M
$1.8B
Q1 24
$1.0B
$843.0M
Total Debt
PLTK
PLTK
RPRX
RPRX
Q4 25
$2.4B
$9.0B
Q3 25
$2.4B
$8.9B
Q2 25
$2.4B
$8.0B
Q1 25
$2.4B
$7.6B
Q4 24
$2.4B
$7.6B
Q3 24
$2.4B
$7.6B
Q2 24
$2.4B
$7.6B
Q1 24
$2.4B
$6.1B
Stockholders' Equity
PLTK
PLTK
RPRX
RPRX
Q4 25
$-411.4M
$9.7B
Q3 25
$-74.8M
$9.6B
Q2 25
$-87.8M
$9.5B
Q1 25
$-117.2M
$9.8B
Q4 24
$-131.1M
$10.3B
Q3 24
$-98.0M
$10.3B
Q2 24
$-112.9M
$9.8B
Q1 24
$-180.4M
$9.9B
Total Assets
PLTK
PLTK
RPRX
RPRX
Q4 25
$3.7B
$19.6B
Q3 25
$3.7B
$19.3B
Q2 25
$3.6B
$18.3B
Q1 25
$3.6B
$17.6B
Q4 24
$3.6B
$18.2B
Q3 24
$3.2B
$18.0B
Q2 24
$3.2B
$17.7B
Q1 24
$3.1B
$16.1B
Debt / Equity
PLTK
PLTK
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PLTK
PLTK
RPRX
RPRX
Operating Cash FlowLast quarter
$285.9M
$827.1M
Free Cash FlowOCF − Capex
$275.2M
FCF MarginFCF / Revenue
40.5%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$531.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PLTK
PLTK
RPRX
RPRX
Q4 25
$285.9M
$827.1M
Q3 25
$116.9M
$702.6M
Q2 25
$146.1M
$364.0M
Q1 25
$18.8M
$596.1M
Q4 24
$153.1M
$742.5M
Q3 24
$156.9M
$703.6M
Q2 24
$150.5M
$658.2M
Q1 24
$29.6M
$664.6M
Free Cash Flow
PLTK
PLTK
RPRX
RPRX
Q4 25
$275.2M
Q3 25
$106.5M
Q2 25
$141.3M
Q1 25
$8.4M
Q4 24
$140.3M
Q3 24
$152.1M
Q2 24
$141.2M
Q1 24
$15.6M
FCF Margin
PLTK
PLTK
RPRX
RPRX
Q4 25
40.5%
Q3 25
15.8%
Q2 25
20.3%
Q1 25
1.2%
Q4 24
21.6%
Q3 24
24.5%
Q2 24
22.5%
Q1 24
2.4%
Capex Intensity
PLTK
PLTK
RPRX
RPRX
Q4 25
1.6%
Q3 25
1.5%
Q2 25
0.7%
Q1 25
1.5%
Q4 24
2.0%
Q3 24
0.8%
Q2 24
1.5%
Q1 24
2.1%
Cash Conversion
PLTK
PLTK
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.99×
2.44×
Q2 25
4.40×
12.06×
Q1 25
0.61×
2.50×
Q4 24
3.57×
Q3 24
3.99×
1.29×
Q2 24
1.74×
6.45×
Q1 24
0.56×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PLTK
PLTK

Third Party Platform$428.7M63%
Other$158.8M23%
Asia Pacific$52.7M8%
Other Geographic Location$38.6M6%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons